Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Public ClinicalTrials.gov record NCT06068868. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-787 in Adult Subjects With Acute Myeloid Leukemia (AML)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Acute myeloid leukemia (AML) is the second most common type of leukemia diagnosed in adults and children, but most cases occur in adults. This study is to evaluate how safe ABBV-787 is and how it moves within the body in adult participants with relapsed/refractory (R/R) acute myeloid leukemia (AML). Adverse events and maximum tolerated dose (MTD) of ABBV-787 will be assessed. ABBV-787 is an investigational drug being developed for the treatment of AML. Participants will receive ABBV-787 in escalating doses until the maximum tolerated dose (MTD) is determined. Approximately 60 adult participants with a diagnosis of AML will be enrolled worldwide. Participants will receive intravenous (IV) infusions of ABBV-787 during the approximately 3 year duration a participant is followed. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests and checking for side effects.
Study identification
- NCT ID
- NCT06068868
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 36 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 12, 2023
- Primary completion
- Feb 24, 2025
- Completion
- Feb 24, 2025
- Last update posted
- Mar 5, 2025
2023 – 2025
United States locations
- U.S. sites
- 14
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope /ID# 253727 | Duarte | California | 91010 | — |
| University of California Davis Health /ID# 252723 | Sacramento | California | 95817 | — |
| Yale University School of Medicine /ID# 252724 | New Haven | Connecticut | 06510 | — |
| Northwestern Memorial Hospital /ID# 252800 | Chicago | Illinois | 60611-2927 | — |
| University of Chicago Medical /ID# 252764 | Chicago | Illinois | 60637 | — |
| University of Maryland, Baltimore /ID# 253726 | Baltimore | Maryland | 21201 | — |
| Cancer & Hematology Centers /ID# 252803 | Grand Rapids | Michigan | 49503 | — |
| Memorial Sloan Kettering Cancer Center-Koch Center /ID# 252515 | New York | New York | 10065-6007 | — |
| Weill Cornell Medical College /ID# 252516 | New York | New York | 10065 | — |
| University of Pennsylvania /ID# 252789 | Philadelphia | Pennsylvania | 19104-5502 | — |
| St. David's South Austin Medical Center /ID# 252790 | Austin | Texas | 78704 | — |
| MD Anderson Cancer Center /ID# 252514 | Houston | Texas | 77030 | — |
| Fred Hutchinson Cancer Research Center /ID# 253730 | Seattle | Washington | 98109-1024 | — |
| Wisconsin Medical Center /ID# 252513 | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06068868, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 5, 2025 · Synced Sep 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06068868 live on ClinicalTrials.gov.